This review aims to summarize several adipokines discovered recently that have promising functions in obesity and T2DM. Among them, the levels of FSTL1, WISP1 and Asprosin in subjects with obesity or diabetes are commonly higher than in normal controls, suggesting that they may be pathogenic. Inversely, SFRP5, Metrnl, NRG4 and FAM19A5 may serve as the protective factors ( Diabetes, Metabolic Syndrome and Obesity)
Diabetes News
Tag: Type 2 Diabetes
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
Our study is limited to aggregate data. In a population of individuals with type 2 diabetes and a high CVD risk, the cardiovascular and renal benefits of SGLT2i remain substantial despite the risk of DKA and even the hypothetical risk of amputation (Diabetologia)
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
The aim of this review is to provide an in-depth summary of CVOT data—crystallising the key findings, from safety to efficacy—and to offer a practical perspective for physicians. Finally, we discuss the next steps for the post-CVOT era, with ongoing studies that may further transform clinical practice and improve outcomes for people with T2D, heart failure or renal disease (Cardiovascular Diabetology)
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI (NEJM)
Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy
Multiple medications are now accepted as being necessary to reduce albuminuria and decelerate the decline in renal function in the patient with diabetic nephropathy (Journal of Diabetes Research)
Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors
Several attributes influence how PwD take their medications. Insights gained directly from PwD have the potential to assist stakeholders in making more informed, patient-centered, treatment decisions, thus choosing and managing medications that PwD are comfortable initiating and persisting with over the longer term (Patient Preference and Adherence)
Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: systematic review and meta-analysis
Our review suggests that inpatient management in the general ward with DPP4i and GLP1Ra is as effective and safe as management with insulin. More randomized studies are required to support these findings before they could be recommended as usual practice (Diabetes Research and Clinical Practice)
The WISDOM self-management intervention: a cost-effectiveness analysis to support the transformation of type 2 diabetes care in England
The WISDOM risk-stratification and education intervention for type 2 diabetes appears to be cost-effective compared to usual care by reducing diabetes complications (Diabetic Medicine)
Increased Serum Trimethylamine N-Oxide Level in Type 2 Diabetic Patients with Mild Cognitive Impairment
Our study showed that T2DM patients with MCI have elevated serum TMAO levels (Metabolic Syndrome and Obesity)
Diabetes: putting people at the heart of services
Diabetes is one of the fastest-growing health challenges of the 21st century. It requires constant self-management and regular contact with healthcare services throughout life. Effective ways to prevent type 2 diabetes, and to manage type 1 and type 2, are available. But more needs to be done to understand how to engage people with services, and how to target care to those who need it most (NIHR)
Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes
In this population-based study, DPP-4 inhibitors were associated with an increased risk of acute liver injury compared with SGLT-2 inhibitors in patients with type 2 diabetes. In contrast, an increased risk of acute liver injury was observed only among female GLP-1 RA users (Diabetes Care)
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Our analyses challenge the adoption of differential blood pressure thresholds, intensities or drug classes in people with and without type 2 diabetes. This study calls for the removal of specific blood pressure thresholds when selecting people with type 2 diabetes for antihypertensive therapy (The Lancet Diabetes & Endocrinology)
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
The study documented benefits of semaglutide on metabolic control and multiple CV risk factors, simplification of therapeutic schemes and high satisfaction with diabetes treatment, and eating behaviors indicative of healthy diet and reduced food intake (Acta Diabetologica)
Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial
DBPR108 as add-on therapy to metformin offered a significant improvement in glycemic control, was superior to metformin monotherapy (placebo), and was safe and well-tolerated in T2DM patients that is inadequately controlled with metformin (Diabetes, Obesity and Metabolism)
Novel Subgroups of Type 2 Diabetes Display Different Epigenetic Patterns That Associate With Future Diabetic Complications
We identified differential epigenetic patterns between T2D subgroups that associated with future diabetic complications. These data support a reclassification of diabetes and the need for precision medicine in T2D subgroups (Diabetes Care)
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
The scope of this American Diabetes Association (ADA) consensus report with designated representation from the American College of Cardiology (ACC) is to provide clear guidance and to recommend best approaches to general internists, primary care providers, and endocrinologists for HF screening, diagnosis, and management in individuals with T1D, T2D, or prediabetes (Diabetes Care)
Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus
The current study evaluates the relation between vitamin D deficiency and the prevalence of albuminuria in the setting of diabetes. Overall, the prevalence of macroalbuminuria increased when the 25OHD serum level was less than 20 ng/ml (BMC Endocrine Disorders)
Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy
A greater increase in the rate of HHF relative to MACE was observed with progressively higher cardiovascular risk, regardless of the risk score applied. Consequently, SGLT2is may offer greater overall cardiovascular protection in those at highest MACE risk, not just those at highest HHF risk (Diabetes Care)
Gut microbiota mediate melatonin signalling in association with type 2 diabetes
These findings uncover the importance of melatonin and melatonin-related bacteria and metabolites as potential therapeutic targets for type 2 diabetes (Diabetologia)
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials
Dipeptidyl peptidase-4 inhibitors increased the risk of cholecystitis in randomised controlled trials, especially with a longer treatment duration, which requires more attention from physicians in clinical practice (BMJ)
- 1
- 2
- 3
- …
- 63
- Next Page »
Glycosmedia is also available as an App: